UTHR Maintained at Buy by Cowen & Co., May 2026

Cowen & Co. reaffirmed its Buy rating on United Therapeutics Corporation (UTHR) on May 21, 2026, maintaining the stock as a top investment idea in the biotech sector. The analyst firm’s decision reflects confidence in UTHR’s pipeline and commercial execution. At $565.87 per share, the stock trades above its 50-day average of $563.20 and well above its 200-day average of $473.40. With a $24 billion market cap and strong analyst consensus, UTHR continues to attract institutional attention.

Cowen & Co. Maintains UTHR Analyst Rating

Cowen & Co. held its Buy rating on United Therapeutics, signaling continued confidence in the company’s strategic direction. The analyst firm views UTHR as a top idea within the biotech space, citing the company’s robust pipeline and market position.

TD Cowen’s coverage emphasizes UTHR’s ability to execute on its commercial therapies and development programs. The rating reflects the analyst’s belief that the company remains well-positioned for growth despite near-term market volatility.

UTHR Financial Metrics and Valuation

United Therapeutics trades at a P/E ratio of 19.14, reflecting moderate valuation relative to biotech peers. The company generated $72.87 in revenue per share and $29.60 in net income per share on a trailing twelve-month basis. With a current ratio of 4.79, UTHR maintains strong liquidity and financial flexibility for R&D investments.

The company’s return on equity stands at 19.24%, demonstrating efficient capital deployment. Operating margins of 45.34% highlight UTHR’s pricing power and operational efficiency in the pulmonary hypertension market.

Analyst Consensus and Market Positioning

Wall Street consensus shows 22 Buy ratings and 2 Hold ratings on UTHR, with no Sell recommendations. This overwhelming bullish sentiment underscores investor confidence in the company’s therapeutic portfolio and pipeline potential. UTHR benefits from its leadership in pulmonary arterial hypertension treatments and expanding indications.

The company’s commercial therapies include Remodulin, Tyvaso, Orenitram, and Unituxin. Development programs like Aurora-GT gene therapy and Ralinepag represent significant growth catalysts for the next 12-24 months.

Meyka AI Stock Grade and Forecast

Meyka AI rates UTHR with a grade of A, reflecting strong fundamentals and growth prospects. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating suggests UTHR is well-positioned relative to peers and the broader market.

Meyka’s price forecasts project UTHR reaching $457.60 by year-end 2026 and $652.62 by 2031. These grades are not guaranteed and we are not financial advisors. The forecasts reflect the company’s pipeline momentum and market expansion potential.

Final Thoughts

Cowen & Co.’s maintained Buy rating on United Therapeutics reflects the biotech company’s strong market position and pipeline potential. With 22 analyst Buy ratings and a Meyka AI grade of A, UTHR demonstrates solid fundamentals and growth prospects. The company’s 19.24% return on equity and 45.34% operating margins underscore operational excellence. Investors should monitor upcoming clinical trial results and commercial execution, particularly for Aurora-GT gene therapy and Ralinepag development. The stock’s valuation at 19.14x P/E remains reasonable for a biotech leader with UTHR’s growth trajectory and market dominance in pulmonary hypertension treatments.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.